Educational links

Medscape

To view the CME, MedScape requires visitors to create a free account.

1. Hypogonadism and cardiovascular and metabolic health: should we consider testosterone replacement?

Test-and-teach 

This activity is intended to improve physicians’ knowledge regarding the recent clinical data on the benefits of testosterone replacement in hypogonadic men with various comorbid conditions, best practice for the accurate detection and diagnosis of male hypogonadism, and optimal treatment strategies for men with hypogonadism.

    Experts

    Geoffrey_Hackett

    Geoffrey Hackett, MD, FRCPI, MRCGP

    Professor of Sexual Medicine, Aston University Birmingham;
    Consultant in Urology and Sexual Medicine, University Hospitals Birmingham;
    Birmingham, United Kingdom

    Learning objectives

    Upon completion of this activity, participants will be able to:

    Have increased knowledge of:
    Hypogonadism in men and its impact on overall health and wellbeing.
    Recent clinical data on the benefits of testosterone replacement in hypogonadic men with various comorbid conditions.
    Demonstrate greater competence in their ability to:
    Accurately detect and diagnose male hypogonadism.
    Employ best practice in the safe and effective treatment of men with hypogonadism.

    Target audience

    This educational activity is intended for an international audience of non-US healthcare professionals, speci­fically diabetologists and endocrinologists, urologists, and primary care physicians involved in the management of patients with, or at risk for, hypogonadism.

    Further information

    (PDF format)

    2. New perspectives on hypogonadism and testosterone replacement in clinical practice

    Expert column 

    The goals of this activity are to help participants identify patients with hypogonadism; provide an overview of the impact of the condition on quality of life and mortality; and review the role of testosterone replacement therapy in prostate, metabolic, and cardiovascular health.

      Experts

      Alvaro Morales

      Alvaro Morales, MD, FRCSC, FACS

      Professor Emeritus, Department of Urology, School of Medicine,
      Queen's University, Kingston,
      Ontario, Canada

      Abraham Morgentaler

      Abraham Morgentaler, MD, FACS

      Founder and Director, Men's Health Boston;
      Associate Clinical Professor of Surgery (Urology),
      Beth Israel Deaconess Medical Center and Harvard Medical School,
      Boston, United States

      Geoffrey_Hackett

      Geoffrey Hackett, MD, FRCPI, MRCGP

      Professor of Sexual Medicine, Aston University Birmingham;
      Consultant in Urology and Sexual Medicine, University Hospitals Birmingham;
      Birmingham, United Kingdom

      Michael Zitzmann

      Michael Zitzmann, MD, PhD

      Professor of Medicine, Endocrinologist, Andrologist, Diabetologist;
      Sexual Medicine (FECSM); Clinical Andrology,
      Centre for Reproductive Medicine and Andrology,
      Münster, Germany

      Learning objectives

      Upon completion of this activity, participants will be able to:

      Identify the clinical impact of testosterone deficiency on men's health, quality of life, and mortality
      Examine the latest clinical data on the interrelationships between hypogonadism and metabolic and cardiovascular risk factors, and between hypogonadism and prostate health
      Explain how to identify men at risk, diagnose hypogonadism, and how to treat and monitor patients, taking into account the latest clinical data and guidelines

      Target audience

      This educational activity is intended for an international audience of non-US healthcare professionals, speci­fically diabetologists and endocrinologists, urologists, and primary care physicians involved in the management of patients with, or at risk for, hypogonadism.

      Further information

      (PDF format)

      Recommendations

      Long term therapy with Nebido®

      Download center

      • PP-NEB-ALL-0347-1

      Copyright © 2019,
      Bayer AG

      This website is intended to provide information to an international audience outside the USA and UK.

      Page last modified Mon, 30/09/2019

      Bayer logo